SEEL(Delisted)
Seelos Therapeutics·NASDAQ
--
--(--)
SEEL fundamentals
Seelos Therapeutics (SEEL) released its earnings on Nov 2, 2017: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Nov 2, 2017
EPS
Revenue
Revenue & Expenses
SEEL has released its 2024 Q2 earnings report, with revenue of 376.00K, reflecting a YoY change of 11.90%, and net profit of 1.71M, showing a YoY change of 105.80%. The Sankey diagram below clearly presents SEEL's revenue sources and cost distribution.
Key Indicators
Seelos Therapeutics (SEEL) key financial stats and ratios, covering profitability, financial health, and leverage.
Seelos Therapeutics (SEEL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Seelos Therapeutics (SEEL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Seelos Therapeutics (SEEL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Seelos Therapeutics (SEEL) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Seelos Therapeutics (SEEL) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
